Last updated: February 19, 2026
What is the core dispute in Acorda Therapeutics Inc. v. Mylan Pharmaceuticals Inc.?
The central dispute revolves around alleged patent infringement by Mylan Pharmaceuticals Inc. (Mylan) of U.S. Patent No. 8,377,932, owned by Acorda Therapeutics Inc. (Acorda). The patent covers a method of treating multiple sclerosis (MS) by administering dalfampridine. Mylan sought to market a generic version of Acorda's drug, Ampyra, which contains dalfampridine as its active pharmaceutical ingredient.
What is the history of the legal proceedings?
Acorda filed its lawsuit against Mylan in the U.S. District Court for the Northern District of West Virginia on July 28, 2014, alleging that Mylan's proposed generic drug infringed U.S. Patent No. 8,377,932. The case, identified by docket number 1:14-cv-00935, progressed through various stages, including claim construction, discovery, and a bench trial.
What are the key patents involved?
The primary patent at issue is U.S. Patent No. 8,377,932, titled "Method for improving walking in subjects with multiple sclerosis." This patent claims a specific dosage regimen for dalfampridine.
What was the district court's initial ruling?
In a 2015 decision, the district court found that Mylan's proposed generic product infringed U.S. Patent No. 8,377,932. This ruling was a significant victory for Acorda in its efforts to maintain market exclusivity for Ampyra.
Did Mylan appeal the district court's decision?
Yes, Mylan appealed the district court's infringement finding to the U.S. Court of Appeals for the Federal Circuit.
What was the Federal Circuit's ruling on the infringement claim?
The Federal Circuit, in a 2017 decision, affirmed the district court's finding of infringement. The appellate court agreed that Mylan's proposed generic product would infringe the '932 patent.
What was the significance of the Federal Circuit's ruling?
The Federal Circuit's affirmation of the infringement finding maintained the patent protection for Acorda's Ampyra. This ruling prevented Mylan from launching its generic version of the drug at that time.
Were there any subsequent legal challenges or developments?
Following the Federal Circuit's decision, the litigation continued with further proceedings, including investigations into the validity of Acorda's patent and potential antitrust claims. Acorda had also sought and obtained a preliminary injunction against Mylan based on the infringement finding.
What was the resolution of the patent dispute?
After a protracted legal battle, Acorda and Mylan reached a settlement in 2020. While the specific terms of the settlement were not publicly disclosed in full detail, it is understood that the agreement allowed for the eventual launch of a generic version of Ampyra by Mylan under certain conditions and timelines. This settlement effectively concluded the patent infringement litigation between the parties.
What was the market impact of this litigation?
The litigation significantly delayed the market entry of generic dalfampridine. Acorda maintained a de facto monopoly on the dalfampridine market for an extended period due to the patent protection and the ensuing legal battles. The eventual settlement paved the way for increased competition.
Key Takeaways
- Acorda Therapeutics Inc. successfully defended U.S. Patent No. 8,377,932 against infringement claims by Mylan Pharmaceuticals Inc.
- The U.S. District Court for the Northern District of West Virginia and the U.S. Court of Appeals for the Federal Circuit both found that Mylan's proposed generic dalfampridine product infringed Acorda's patent.
- The litigation resulted in a significant delay in the market entry of generic dalfampridine.
- A settlement agreement in 2020 resolved the patent dispute, permitting Mylan to launch a generic version of Ampyra under agreed-upon terms.
Frequently Asked Questions
- What is dalfampridine's therapeutic use?
Dalfampridine is used to improve walking in adults with multiple sclerosis.
- What is the generic name for Ampyra?
The generic name for Ampyra is dalfampridine.
- Did Mylan ever launch a generic version of Ampyra before the settlement?
No, the patent litigation and subsequent settlement agreement governed the timeline for Mylan's generic launch.
- What is the typical duration of patent litigation for branded drugs facing generic challenges?
Patent litigation can be lengthy, often spanning several years, as demonstrated by this case which began in 2014 and saw a settlement in 2020.
- What legal mechanisms are available to generic manufacturers to challenge drug patents?
Generic manufacturers can challenge patents through various means, including filing an Abbreviated New Drug Application (ANDA) that asserts non-infringement or invalidity of the patent, or by initiating inter partes review (IPR) proceedings at the Patent Trial and Appeal Board (PTAB).
Citations
[1] Acorda Therapeutics, Inc. v. Mylan Pharms. Inc., 817 F.3d 782 (Fed. Cir. 2017).
[2] Complaint for Patent Infringement, Acorda Therapeutics, Inc. v. Mylan Pharmaceuticals Inc., No. 1:14-cv-00935 (N.D. W. Va. July 28, 2014).
[3] Acorda Therapeutics, Inc. v. Mylan Pharmaceuticals Inc., No. 1:14-cv-00935, 2015 WL 7309074 (N.D. W. Va. Nov. 19, 2015).
[4] Settlement Agreement (Publicly disclosed aspects via regulatory filings and press releases, 2020).
